Capell H A
Center Rheumatic Disease Ward 14-15, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, Scotland G40SF.
J Rheumatol Suppl. 2001 Jun;62:10-5.
The trend for more aggressive management of rheumatoid arthritis includes earlier introduction of disease modifying antirheumatic drugs (DMARD). As patients may continue their therapy for several decades instead of several years, the evaluation of benefit versus risk of DMARD with particular emphasis on longterm safety is essential. Longterm safety assessment is difficult for a number of reasons: there are relatively few trials that have followed patients beyond 5 years and the use of a combination of DMARD therapy with nonsteroidal antiinflammatory drugs and corticosteroids complicates the assessment of an observed adverse event with a particular drug. This review of longterm studies incorporating DMARD provides insight into adverse events associated with currently available DMARD.
类风湿关节炎更积极治疗的趋势包括更早引入改善病情抗风湿药（DMARD）。由于患者可能要持续治疗数十年而非数年，因此评估DMARD的获益与风险，尤其关注长期安全性至关重要。长期安全性评估存在诸多困难：随访患者超过5年的试验相对较少，且DMARD疗法与非甾体抗炎药和皮质类固醇联合使用使对某种特定药物观察到的不良事件的评估变得复杂。这篇纳入DMARD的长期研究综述深入探讨了与现有DMARD相关的不良事件。
